Frank Scott
Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 27 | 2025 | 351 | 8.060 |
Why?
| | Crohn Disease | 14 | 2025 | 243 | 4.260 |
Why?
| | Colitis, Ulcerative | 9 | 2025 | 136 | 2.160 |
Why?
| | Gastrointestinal Agents | 5 | 2024 | 65 | 1.640 |
Why?
| | Infliximab | 10 | 2022 | 111 | 1.590 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 51 | 1.510 |
Why?
| | Gastroenterology | 6 | 2024 | 180 | 1.390 |
Why?
| | Tissue Adhesions | 3 | 2021 | 32 | 1.290 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 890 | 1.280 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1242 | 1.130 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 565 | 1.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 804 | 0.990 |
Why?
| | Intestine, Small | 2 | 2021 | 156 | 0.990 |
Why?
| | Algorithms | 6 | 2020 | 1704 | 0.910 |
Why?
| | JC Virus | 2 | 2015 | 23 | 0.900 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 37 | 0.880 |
Why?
| | Azathioprine | 5 | 2021 | 54 | 0.830 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 63 | 0.810 |
Why?
| | Abdomen | 2 | 2021 | 125 | 0.780 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 321 | 0.770 |
Why?
| | Abdominal Abscess | 1 | 2022 | 27 | 0.770 |
Why?
| | Biological Products | 3 | 2023 | 216 | 0.760 |
Why?
| | Humans | 88 | 2025 | 137585 | 0.750 |
Why?
| | Postoperative Complications | 3 | 2021 | 2654 | 0.720 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 132 | 0.710 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1809 | 0.680 |
Why?
| | Ustekinumab | 1 | 2020 | 15 | 0.680 |
Why?
| | Splints | 1 | 2020 | 15 | 0.680 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 18 | 0.670 |
Why?
| | Antibodies, Viral | 2 | 2015 | 625 | 0.670 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 23 | 0.660 |
Why?
| | Barrett Esophagus | 4 | 2023 | 149 | 0.640 |
Why?
| | Radius Fractures | 1 | 2020 | 59 | 0.640 |
Why?
| | Biomedical Research | 2 | 2019 | 692 | 0.630 |
Why?
| | Retrospective Studies | 26 | 2023 | 15657 | 0.630 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 113 | 0.600 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 445 | 0.600 |
Why?
| | Spondylarthritis | 3 | 2025 | 50 | 0.600 |
Why?
| | Colonoscopy | 7 | 2024 | 245 | 0.590 |
Why?
| | Drug Utilization | 1 | 2019 | 169 | 0.580 |
Why?
| | Intestinal Fistula | 1 | 2018 | 17 | 0.570 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 259 | 0.570 |
Why?
| | Health Resources | 1 | 2019 | 120 | 0.570 |
Why?
| | Colonic Diseases | 1 | 2018 | 33 | 0.570 |
Why?
| | Pericardium | 1 | 2018 | 55 | 0.560 |
Why?
| | Tuberculin Test | 1 | 2017 | 36 | 0.560 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 591 | 0.560 |
Why?
| | Biological Factors | 2 | 2023 | 39 | 0.540 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 98 | 0.540 |
Why?
| | Models, Statistical | 2 | 2019 | 669 | 0.540 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 69 | 0.520 |
Why?
| | Time-to-Treatment | 2 | 2019 | 205 | 0.520 |
Why?
| | Mass Screening | 4 | 2021 | 1287 | 0.520 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 806 | 0.510 |
Why?
| | Male | 47 | 2025 | 67762 | 0.500 |
Why?
| | Adult | 35 | 2025 | 37929 | 0.490 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1430 | 0.490 |
Why?
| | Middle Aged | 36 | 2025 | 33479 | 0.480 |
Why?
| | Radius | 1 | 2015 | 39 | 0.470 |
Why?
| | Natalizumab | 1 | 2015 | 40 | 0.470 |
Why?
| | Hospitalization | 3 | 2022 | 2199 | 0.460 |
Why?
| | Heart Diseases | 1 | 2018 | 346 | 0.450 |
Why?
| | Fracture Fixation | 1 | 2015 | 75 | 0.450 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 314 | 0.440 |
Why?
| | Models, Theoretical | 1 | 2018 | 578 | 0.430 |
Why?
| | Age Factors | 5 | 2025 | 3295 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1313 | 0.420 |
Why?
| | Aged | 27 | 2024 | 23961 | 0.420 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2828 | 0.410 |
Why?
| | Markov Chains | 3 | 2020 | 126 | 0.400 |
Why?
| | Lymphoma | 1 | 2014 | 208 | 0.400 |
Why?
| | Female | 43 | 2025 | 73304 | 0.400 |
Why?
| | Risk Factors | 17 | 2025 | 10388 | 0.390 |
Why?
| | Patient Acceptance of Health Care | 4 | 2024 | 806 | 0.390 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1066 | 0.380 |
Why?
| | Adalimumab | 3 | 2021 | 48 | 0.380 |
Why?
| | Communicable Diseases | 1 | 2014 | 159 | 0.380 |
Why?
| | Patient Discharge | 2 | 2023 | 897 | 0.370 |
Why?
| | United Kingdom | 5 | 2021 | 318 | 0.360 |
Why?
| | Gastroenterologists | 2 | 2022 | 18 | 0.360 |
Why?
| | Professional Competence | 1 | 2012 | 100 | 0.360 |
Why?
| | Disease Management | 3 | 2021 | 628 | 0.350 |
Why?
| | Cohort Studies | 10 | 2025 | 5742 | 0.340 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 350 | 0.340 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 46 | 0.340 |
Why?
| | Fractures, Bone | 1 | 2015 | 380 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 683 | 0.330 |
Why?
| | Research Design | 2 | 2019 | 1139 | 0.330 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 234 | 0.330 |
Why?
| | Research Personnel | 1 | 2012 | 173 | 0.330 |
Why?
| | Treatment Outcome | 12 | 2024 | 10811 | 0.330 |
Why?
| | Colonic Polyps | 2 | 2024 | 88 | 0.320 |
Why?
| | Adenoma | 3 | 2024 | 230 | 0.320 |
Why?
| | United States | 17 | 2025 | 14841 | 0.320 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1266 | 0.310 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 252 | 0.300 |
Why?
| | Pediatric Obesity | 1 | 2016 | 601 | 0.300 |
Why?
| | Skin Neoplasms | 1 | 2016 | 855 | 0.290 |
Why?
| | Quality of Life | 2 | 2021 | 2892 | 0.280 |
Why?
| | Electronic Health Records | 6 | 2022 | 1069 | 0.280 |
Why?
| | Incidence | 8 | 2021 | 2804 | 0.280 |
Why?
| | Remission Induction | 2 | 2024 | 288 | 0.270 |
Why?
| | Databases, Factual | 7 | 2018 | 1357 | 0.260 |
Why?
| | Mortality | 2 | 2020 | 362 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 1079 | 0.250 |
Why?
| | Radiography | 2 | 2020 | 822 | 0.240 |
Why?
| | Referral and Consultation | 2 | 2023 | 786 | 0.240 |
Why?
| | Population Surveillance | 2 | 2021 | 482 | 0.240 |
Why?
| | Antifungal Agents | 2 | 2016 | 136 | 0.230 |
Why?
| | Aged, 80 and over | 10 | 2020 | 7635 | 0.230 |
Why?
| | Case-Control Studies | 8 | 2021 | 3556 | 0.220 |
Why?
| | Recurrence | 5 | 2021 | 1060 | 0.220 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 54 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 951 | 0.210 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 5778 | 0.210 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 697 | 0.210 |
Why?
| | Adenocarcinoma | 2 | 2021 | 940 | 0.210 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 89 | 0.210 |
Why?
| | Obesity | 1 | 2017 | 2992 | 0.210 |
Why?
| | Colectomy | 2 | 2021 | 100 | 0.200 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 15 | 0.200 |
Why?
| | Protective Factors | 2 | 2021 | 93 | 0.200 |
Why?
| | Models, Economic | 2 | 2020 | 58 | 0.200 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 259 | 0.200 |
Why?
| | Logistic Models | 6 | 2018 | 2074 | 0.200 |
Why?
| | Glucocorticoids | 2 | 2018 | 594 | 0.200 |
Why?
| | Comparative Effectiveness Research | 2 | 2024 | 152 | 0.190 |
Why?
| | Prognosis | 4 | 2019 | 4030 | 0.190 |
Why?
| | Cellulitis | 1 | 2022 | 53 | 0.190 |
Why?
| | Medical Marijuana | 1 | 2024 | 117 | 0.190 |
Why?
| | Odds Ratio | 4 | 2018 | 1070 | 0.190 |
Why?
| | Insurance, Health | 1 | 2024 | 283 | 0.180 |
Why?
| | Necrosis | 1 | 2022 | 246 | 0.180 |
Why?
| | Amputation, Traumatic | 1 | 2021 | 20 | 0.180 |
Why?
| | Finger Injuries | 1 | 2021 | 23 | 0.180 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 303 | 0.180 |
Why?
| | Rectal Fistula | 1 | 2021 | 28 | 0.180 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 938 | 0.180 |
Why?
| | Aftercare | 1 | 2023 | 208 | 0.170 |
Why?
| | Prevalence | 4 | 2025 | 2734 | 0.170 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5131 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2021 | 871 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2024 | 279 | 0.170 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 63 | 0.170 |
Why?
| | Feces | 2 | 2022 | 484 | 0.170 |
Why?
| | Esophagoscopy | 2 | 2022 | 209 | 0.170 |
Why?
| | Cystectomy | 2 | 2017 | 37 | 0.170 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2020 | 32 | 0.170 |
Why?
| | Utilization Review | 1 | 2020 | 36 | 0.170 |
Why?
| | Sugars | 1 | 2020 | 41 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 106 | 0.160 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 35 | 0.160 |
Why?
| | Bone Density | 1 | 2023 | 489 | 0.160 |
Why?
| | Bone Plates | 1 | 2020 | 77 | 0.160 |
Why?
| | Carcinoma | 1 | 2021 | 240 | 0.160 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1040 | 0.160 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 120 | 0.160 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 322 | 0.160 |
Why?
| | Tryptophan | 1 | 2021 | 183 | 0.160 |
Why?
| | Metagenomics | 1 | 2021 | 169 | 0.160 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1946 | 0.150 |
Why?
| | Hospitals | 2 | 2021 | 691 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2021 | 143 | 0.150 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 252 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2023 | 264 | 0.150 |
Why?
| | Chronic Disease | 2 | 2022 | 1793 | 0.150 |
Why?
| | Child | 6 | 2023 | 21935 | 0.150 |
Why?
| | Metabolomics | 2 | 2022 | 678 | 0.150 |
Why?
| | Diverticulum | 1 | 2018 | 12 | 0.150 |
Why?
| | Job Satisfaction | 1 | 2021 | 218 | 0.150 |
Why?
| | Hematemesis | 1 | 2018 | 3 | 0.150 |
Why?
| | Health Care Costs | 1 | 2021 | 398 | 0.140 |
Why?
| | Infant | 5 | 2020 | 9465 | 0.140 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 289 | 0.140 |
Why?
| | Fracture Fixation, Internal | 1 | 2020 | 188 | 0.140 |
Why?
| | Symptom Assessment | 2 | 2017 | 128 | 0.140 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 393 | 0.140 |
Why?
| | Intestines | 1 | 2021 | 357 | 0.140 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 25 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2021 | 546 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2018 | 73 | 0.140 |
Why?
| | Fatal Outcome | 1 | 2018 | 303 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1167 | 0.130 |
Why?
| | Risk Assessment | 3 | 2016 | 3457 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 642 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 13 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 284 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1477 | 0.130 |
Why?
| | Itraconazole | 1 | 2016 | 6 | 0.130 |
Why?
| | Budesonide | 1 | 2016 | 89 | 0.120 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 19 | 0.120 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 56 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1000 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 228 | 0.120 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 72 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 556 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5472 | 0.120 |
Why?
| | Cysts | 1 | 2016 | 113 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 120 | 0.120 |
Why?
| | Epiphyses | 1 | 2015 | 25 | 0.120 |
Why?
| | Child, Preschool | 5 | 2016 | 11074 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 118 | 0.120 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 293 | 0.120 |
Why?
| | Data Accuracy | 1 | 2015 | 65 | 0.120 |
Why?
| | Societies, Medical | 3 | 2024 | 820 | 0.120 |
Why?
| | Psoriasis | 1 | 2016 | 102 | 0.110 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 56 | 0.110 |
Why?
| | Polypharmacy | 1 | 2015 | 85 | 0.110 |
Why?
| | Adolescent | 7 | 2019 | 21513 | 0.110 |
Why?
| | Neoplasms | 2 | 2023 | 2671 | 0.110 |
Why?
| | Elbow Joint | 1 | 2015 | 71 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 195 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2015 | 109 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2017 | 789 | 0.110 |
Why?
| | Young Adult | 7 | 2019 | 13209 | 0.110 |
Why?
| | Dilatation | 1 | 2014 | 67 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2021 | 442 | 0.110 |
Why?
| | Cholesterol | 1 | 2016 | 410 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 762 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 236 | 0.110 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 153 | 0.110 |
Why?
| | Streptococcal Infections | 1 | 2016 | 151 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 212 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2014 | 145 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 617 | 0.100 |
Why?
| | Foreign Bodies | 1 | 2014 | 104 | 0.100 |
Why?
| | Disease Progression | 2 | 2021 | 2757 | 0.100 |
Why?
| | Registries | 1 | 2021 | 2035 | 0.100 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 447 | 0.100 |
Why?
| | Reoperation | 1 | 2015 | 573 | 0.100 |
Why?
| | Primary Health Care | 2 | 2022 | 1738 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 308 | 0.090 |
Why?
| | Diabetes Complications | 1 | 2013 | 227 | 0.090 |
Why?
| | Epidemiology | 1 | 2012 | 33 | 0.090 |
Why?
| | Patient Readmission | 1 | 2017 | 697 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 321 | 0.090 |
Why?
| | Endoscopy | 1 | 2014 | 318 | 0.090 |
Why?
| | Biomarkers | 2 | 2020 | 4149 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 119 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 392 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 6828 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2031 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 910 | 0.080 |
Why?
| | Veterans | 1 | 2021 | 1476 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7604 | 0.080 |
Why?
| | Medicare | 3 | 2021 | 773 | 0.070 |
Why?
| | Drug Prescriptions | 2 | 2024 | 245 | 0.070 |
Why?
| | Laparoscopy | 1 | 2012 | 466 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2069 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1389 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2021 | 512 | 0.060 |
Why?
| | Pennsylvania | 2 | 2017 | 116 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 889 | 0.060 |
Why?
| | Sex Factors | 2 | 2025 | 2071 | 0.060 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 26 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2253 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1325 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1509 | 0.050 |
Why?
| | Regression Analysis | 2 | 2017 | 1024 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 206 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 230 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 126 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 683 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.040 |
Why?
| | Cost Savings | 1 | 2021 | 84 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 50 | 0.040 |
Why?
| | Fingers | 1 | 2021 | 88 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 75 | 0.040 |
Why?
| | Documentation | 1 | 2023 | 194 | 0.040 |
Why?
| | Training Support | 1 | 2021 | 35 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 56 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 740 | 0.040 |
Why?
| | Hand | 1 | 2021 | 156 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 324 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 180 | 0.040 |
Why?
| | Perception | 1 | 2022 | 359 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3284 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 227 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 181 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 211 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 121 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 518 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 219 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 91 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 328 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 23 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 31 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 226 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 50 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1627 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 240 | 0.030 |
Why?
| | Mercaptopurine | 1 | 2016 | 16 | 0.030 |
Why?
| | Hip Fractures | 1 | 2018 | 86 | 0.030 |
Why?
| | Etanercept | 1 | 2016 | 57 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2844 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1118 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 644 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 56 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 900 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 746 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 45 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 434 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 623 | 0.030 |
Why?
| | Weight Loss | 1 | 2021 | 787 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 260 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 431 | 0.030 |
Why?
| | Bias | 1 | 2016 | 218 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 510 | 0.030 |
Why?
| | Mental Recall | 1 | 2015 | 202 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 978 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1774 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 435 | 0.030 |
Why?
| | Anticoagulants | 1 | 2018 | 664 | 0.030 |
Why?
| | Waiting Lists | 1 | 2015 | 266 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1587 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1996 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 390 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2111 | 0.010 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|